Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lecanemab in Early Alzheimer's Disease
NCT07034222Phase 4Active, not recruiting
- Sponsor
- Ruijin Hospital
- Start
- Feb 2024
- Primary completion
- Jan 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 4 trial of lecanemab in Alzheimer's disease (AD), sponsored by Ruijin Hospital. Started Feb 2024; status: active, not recruiting.
02
Drugs
lecanemab
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT07034222.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07034222.